Biosimilar conversion from the reference to biosimilar filgrastim enabled expanded access to ado-trastuzumab emtansine, ranging from 61 to 191 patients with locally advanced HER2/neu-positive breast cancer in adjuvant settings [3]. Here, ERBB2 is linked to breast carcinoma.